title: Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
authors.forename: Antonio
authors.initials: A
authors.lastname: Juan
authors.forename: Bartolome
authors.initials: B
authors.lastname: Ribas
authors.forename: Cristina
authors.initials: C
authors.lastname: Nadal
authors.forename: Imnaculada
authors.initials: I
authors.lastname: Ros
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept